A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

Summary

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: Are 18 to 64 years of age; Were confirmed to have AD at least 6 months ago; Do not have a suitable prescribed medicine for AD; Are considered by their doctors to have moderate to severe AD. The study has two stages (Stage 1 and Stage 2).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Atopic Dermatitis
• Eczema, Atopic

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 64 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

October 13, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites